Jamjoom Pharmaceuticals Factory Co. 4015

TADAWUL · Saudi Arabia · Health Technology

SAR 126.80+0.60 (+0.48%)

Market closed· Oct 1, 2026, 12:10 PM UTC· SAR · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Jamjoom Pharmaceuticals Factory Co. 4015

TADAWUL · Saudi Arabia · Health Technology

SAR 126.80+0.60 (+0.48%)

Market closed· Oct 1, 2026, 12:10 PM UTC· SAR · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-12.19% · 6MFull-screen chart

Open SAR 126.20High SAR 127.00Low SAR 125.50Close SAR 126.80Volume 16.76K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: SAR 126.20
Day range: SAR 125.50 – SAR 127.00
52-week range: SAR 125.00 – SAR 165.30
Volume: 16.76K
Market cap: SAR 8.83B
P/E (TTM): 18.5
Dividend yield (annualized): 3.33%
Next earnings date: 2026-10-27
Avg. volume (1Y): 60.33K

Performance

1 week

-1.96%

1 month

-6.54%

3 months

-14.69%

6 months

-8.43%

Year to date

-6.78%

1 year

-14.12%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Saudi Arabia
Exchange: TADAWUL
Shares outstanding: 70.00M
Employees: 1,130
ISIN: SA15QGU1UNH6
Beta: 0.45

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJul 27, 2026

Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant

Exclusive agreement with Jamjoom Pharma covers commercialization and distribution of QUVIVIQ™ (daridorexant) in Saudi Arabia and the Levant region Allschwil, Switzerland – July 27, 2026Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Jamjoom Pharmaceuticals Factory Co. (“Jamjoom Pharma”) for the distribution and commercialization of QUVIVIQ™ (daridorexant), Idorsia’s treatment for adults with insomnia, in Saudi Arabia and the Levant region. Benjamin Limal, President of Europe

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.